{"id":59342,"date":"2015-09-17T08:00:34","date_gmt":"2015-09-17T12:00:34","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=59342"},"modified":"2015-09-16T19:40:25","modified_gmt":"2015-09-16T23:40:25","slug":"study-329-vii-variable-variables","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2015\/09\/17\/study-329-vii-variable-variables\/","title":{"rendered":"study 329 vii &#8211; <em>variable<\/em> variables?&#8230;"},"content":{"rendered":"\n<p align=\"center\"><sup><em><strong>WARNING:<\/strong> Sometimes the devil is in the details. Here, we need to get pretty far into the details&#8230;<\/em><\/sup><\/p>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" align=\"center\">\n<tr class=\"small\">\n<td align=\"center\" colspan=\"3\"><strong><font color=\"#200020\">RATING SCALES<\/font><\/strong>                             <\/p>\n<hr size=\"1\" \/><\/td>\n<\/tr>\n<tr class=\"small\">\n<td align=\"right\"><strong><font color=\"#200020\">HAM-D<\/font><\/strong><\/td>\n<td rowspan=\"6\">&nbsp;&nbsp;&nbsp;<\/td>\n<td>Hamilton Depression Rating Scale<\/td>\n<\/tr>\n<tr class=\"small\">\n<td align=\"right\"><strong><font color=\"#200020\">K-SADS-L<\/font><\/strong><\/td>\n<td>Kiddie Schedule for Affective Disorders &#8211; Lifetime<\/td>\n<\/tr>\n<tr class=\"small\">\n<td align=\"right\"><strong><font color=\"#200020\">CGI<\/font><\/strong><\/td>\n<td>Clinical Global Impressions Scale<\/td>\n<\/tr>\n<tr class=\"small\">\n<td align=\"right\"><strong><font color=\"#200020\">AFC<\/font><\/strong><\/td>\n<td>Autonomous Function Checklist<\/td>\n<\/tr>\n<tr class=\"small\">\n<td align=\"right\"><strong><font color=\"#200020\">SPP<\/font><\/strong><\/td>\n<td>Self-Perception Profile<\/td>\n<\/tr>\n<tr class=\"small\">\n<td align=\"right\"><strong><font color=\"#200020\">SIP<\/font><\/strong><\/td>\n<td>Sickness Impact Profile<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\" class=\"small\">It is essential in Clinical Trials to declare the specific outcome variables and the statistical analytic methodology in the a priori protocol [before the study begins]. That&#8217;s the only way to assure that the methodology hasn&#8217;t been adjusted, jury-rigged to make the data look a certain way. The standard is to not even allow for the possibility of mistrust. And any changes to the a priori protocol need to be added in as an amendment or modification, approved by the certifying agency ie the Institutional Review Board [IRB]. In a recent study of Clinical Trials in Psychiatry [<a href=\"http:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0133718\" target=\"_blank\">Is Mandatory Prospective Trial Registration Working to Prevent Publication of Unregistered Trials and Selective Outcome Reporting?<\/a>], only one third of the studies from the five journals with the highest impact rating in Psychiatry abided by this rule, and in the end, only 14% of the total cohort carried out the analysis precisely as described in the a priori protocol &#8211; even though it was a requirement for publication in all five journals.<\/p>\n<div align=\"justify\" class=\"small\">The protocol for Paxil Study 329 was written well before the actual Clinical Trial began and was quite clear in reference to the outcome variables. They are unambiguously declared in the <a href=\"http:\/\/www.healthyskepticism.org\/files\/docs\/gsk\/paroxetine\/study329\/Protocol329.pdf#page=5\" target=\"_blank\">a priori protocol<\/a>:<\/div>\n<blockquote>\n<div align=\"justify\"><u><strong><font color=\"#200020\">Primary Efficacy Variables<\/font><\/strong><\/u><\/div>\n<div align=\"justify\">&bull; Change in total HAMD score from beginning of treatment phase to the endpoint of the acute phase.<\/div>\n<div align=\"justify\">&bull; The proportion of responders at the end of the eight week acute treatment phase. &quot;Responders are defined as 50% or greater reduction in the HAM-D or a HAM-D score equal to or less than 8.<\/div>\n<div align=\"justify\"><u><strong><font color=\"#200020\">Secondary Efficacy Variables<\/font><\/strong><\/u><\/div>\n<div align=\"justify\">&bull; Change from baseline to endpoint (acute phase) in the depression items of the K-SADS-L, global impressions, autonomic function checklist, self perception profile and sickness impact scale.<\/div>\n<div align=\"justify\">&bull; The number of patients who relapse during the maintenance phase.<\/div>\n<\/blockquote>\n<div align=\"justify\" class=\"small\">Likewise, the requirements for <a href=\"http:\/\/www.healthyskepticism.org\/files\/docs\/gsk\/paroxetine\/study329\/Protocol329.pdf#page=5\" target=\"_blank\">changing the protocol<\/a> are explicit:<\/div>\n<blockquote>\n<div align=\"left\"><strong><font color=\"#200020\">PROTOCOL AMENDMENTS<\/font><\/strong><\/div>\n<div align=\"justify\">No changes to the study           protocol will be allowed unless discussed in <font>detail with the SmithKline Beecham (SB) Medical&nbsp;           Monitor and filed as <\/font><font>an           amendment\/modification to this protocol. <\/font><font>Any amendment\/modification to the protocol will           be adhered to by the <\/font><font>participating           centre (or all participating centres) and will apply to all <\/font><font>subjects following approval as appropriate by the           Ethical Review <\/font><font>Committee or           Institutional Review Board.<\/font><\/div>\n<\/blockquote>\n<div align=\"justify\" class=\"small\">Yet in the published 2001 paper, we find that some of the outcome variables have been changed [in the <a href=\"http:\/\/www.justice.gov\/sites\/default\/files\/opa\/legacy\/2012\/07\/02\/complaint-ex2.pdf#page=3\" target=\"_blank\">Efficacy and Safety Evaluation<\/a> Section]:<\/div>\n<blockquote>\n<div align=\"justify\">&quot;The <strong><font color=\"#990000\">protocol described<\/font><\/strong> two primary outcome measures: (1) response, which was defined as a HAM-D score of &lt;8 or a &gt;50% reduction in baseline HAM-D score at the end of treatment; and (2) change from baseline in HAM-D total score. Five other <strong><font color=\"#990000\">depression-related variables<\/font><\/strong> were <strong><font color=\"#990000\">declared a priori<\/font><\/strong>: (1) change in the depressed mood item of the HAM-D; (2) change in the depression item of the K-SADS-L; (3) Clinical Global Impression (CGI) improvement scores&nbsp; of 1 (very much improved) or 2 (much improved); (4) change in the nine-item depression subscale of the K-SADS-L; and (5) mean CGI improvement scores.&quot;<\/div>\n<\/blockquote>\n<div align=\"justify\" class=\"small\">Notice that the two primary outcome measures are identified as <strong><font color=\"#990000\">protocol described<\/font><\/strong>, whereas the remaining five are not labeled as coming from the protocol, nor are they called secondary outcome variables. Instead, they&#8217;re identified as <strong><font color=\"#990000\">depression-related variables<\/font><\/strong> and <strong><font color=\"#990000\">declared a priori<\/font><\/strong>. Then later in the article, there&#8217;s yet a different version in the <a href=\"http:\/\/www.justice.gov\/sites\/default\/files\/opa\/legacy\/2012\/07\/02\/complaint-ex2.pdf#page=5\" target=\"_blank\">Efficacy Results<\/a> section text and Table 2 [page 766], adding in <strong><font color=\"#990000\">response<\/font><\/strong>:<\/div>\n<blockquote>\n<div align=\"justify\">Of the depression-related variables, paroxetine separated statistically from placebo at endpoint among four of the parameters: <strong><font color=\"#990000\">response<\/font><font color=\"#990000\"> (i.e., primary outcome measure)<\/font><\/strong>, HAM-D depressed mood item, K-SADS-L depressed mood item, and CGI score of 1 (very much improved) or 2 (much improved) and trended toward statistical significance on two measures (K-SADS-L nine-item depression subscore and mean CGI score).<\/div>\n<\/blockquote>\n<div align=\"center\"><img decoding=\"async\" width=\"510\" border=\"0\" src=\"http:\/\/1boringoldman.com\/images\/329-table-2.gif\" \/><br \/> <sup>non-protocol variables in blue<br \/><\/sup><\/div>\n<p align=\"justify\" class=\"small\">I&#8217;ve colored the non-protocol variables blue. Those differences are the very devil in the details that are unexplained in the article itself. In fact, without having the protocol in hand, one would not likely notice them [and very few did&nbsp; notice them]. Here&#8217;s a summary of the various versions:<\/p>\n<p align=\"center\"><img loading=\"lazy\" decoding=\"async\" width=\"500\" border=\"0\" height=\"290\" src=\"http:\/\/1boringoldman.com\/images\/329-table-2.jpg\" \/><\/p>\n<p align=\"justify\" class=\"small\">This discrepancy is what caught the attention of a few early nay-sayers about this article. <strong><font color=\"#990000\">All four of the significant variables in Table 2 are nowhere mentioned in the protocol,<\/font><\/strong> so the designation, <strong><font color=\"#990000\">a priori<\/font><\/strong>, doesn&#8217;t really make a bit of sense. For that matter, why use the term <strong><font color=\"#990000\">depression-related<\/font><\/strong> rather than Secondary? And where did <em><strong><font color=\"#990000\">response<\/font><\/strong><\/em> [HAM-D <u>&lt;<\/u>8] come from? In order to explain these changes, you have to have the 500+ page <font color=\"#200020\">CSR <\/font>[<a target=\"_blank\" href=\"https:\/\/www.gsk.com\/media\/389566\/depression_329_full.pdf\">Clinical Study Report<\/a>] available and a keen eye. And recall that the <font color=\"#200020\">CSR<\/font> only became available as part of the 2004 settlement between <strong><font color=\"#cc0000\">GSK<\/font><\/strong> and the State of New York.<\/p>\n<div align=\"justify\" class=\"small\">So far, only questions, but some answers are just around the corner&#8230;<\/div>\n","protected":false},"excerpt":{"rendered":"<p>WARNING: Sometimes the devil is in the details. Here, we need to get pretty far into the details&#8230; RATING SCALES HAM-D &nbsp;&nbsp;&nbsp; Hamilton Depression Rating Scale K-SADS-L Kiddie Schedule for Affective Disorders &#8211; Lifetime CGI Clinical Global Impressions Scale AFC Autonomous Function Checklist SPP Self-Perception Profile SIP Sickness Impact Profile It is essential in Clinical [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-59342","post","type-post","status-publish","format-standard","hentry","category-opinion"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/59342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=59342"}],"version-history":[{"count":43,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/59342\/revisions"}],"predecessor-version":[{"id":59995,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/59342\/revisions\/59995"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=59342"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=59342"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=59342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}